Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - atorvastatin calcium trihydrate, quantity: 10.845 mg (equivalent: atorvastatin, qty mg) - tablet, film coated - excipient ingredients: polysorbate 80; lactose monohydrate; hyprolose; microcrystalline cellulose; croscarmellose sodium; calcium carbonate; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1, pharmacodynamic properties, clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - atorvastatin calcium trihydrate, quantity: 86.76 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium carbonate; hyprolose; croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; polysorbate 80; titanium dioxide; macrogol 8000; hypromellose; purified talc - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1, pharmacodynamic properties, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Canada - English - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

apotex inc - atorvastatin (atorvastatin calcium propylene glycol solvate) - tablet - 10mg - atorvastatin (atorvastatin calcium propylene glycol solvate) 10mg - hmg-coa reductase inhibitors

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 10.85mg equivalent to 10 mg atorvastatin;   - film coated tablet - 10 mg - active: atorvastatin calcium 10.85mg equivalent to 10 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.